Cereno Scientific obtains the right to inlicense a preclinical candidate from University of Michigan through an option agreement
Cereno Scientific today announced that an option agreement has been signed with the University of Michigan obtaining the exclusive rights to evaluate the market potential for a preclinical drug candidate. The agreement grants Cereno the rights to evaluate the drug candidate in a preclinical development program during a time period of up to 27 months. If the evaluation is successful, Cereno can exclusively inlicense the drug for further clinical development and commercialization. This marks an expansion of Cereno’s project portfolio with a promising preclinical drug candidate in cardiovascular